{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:10:51Z","timestamp":1793297451653,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T00:00:00Z","timestamp":1540166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T00:00:00Z","timestamp":1540166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To evaluate clinical outcomes in patients with diabetes, treated by cardiac resynchronization therapy with a defibrillator (CRT-d), and glucagon-like peptide 1 receptor agonists (GLP-1 RA) in addition to conventional hypoglycemic therapy vs. CRTd patients under conventional hypoglycemic drugs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with diabetes treated by CRTd experienced an amelioration of functional New York Association Heart class, reduction of hospital admissions, and mortality, in a percentage about 60%. However, about 40% of CRTd patients with diabetes experience a worse prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>We investigated the 12-months prognosis of CRTd patients with diabetes, previously treated with hypoglycemic drugs therapy (n 271) vs. a matched cohort of CRTd patients with diabetes treated with GLP-1 RA in addition to conventional hypoglycemic therapy (n 288).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At follow up CRTd patients with diabetes treated by GLP-1 RA therapy vs. CRTd patients with diabetes that did not receive GLP-1 RA therapy, experienced a significant reduction of NYHA class (p value\u2009&lt;\u20090.05), associated to higher values of 6\u00a0min walking test (p value\u2009&lt;\u20090.05), and higher rate of CRTd responders (p value\u2009&lt;\u20090.05). GLP-1 RA patients vs. controls at follow up end experienced lower AF events (p value\u2009&lt;\u20090.05), lower VT events (p value\u2009&lt;\u20090.05), lower rate of hospitalization for heart failure worsening (p value\u2009&lt;\u20090.05), and higher rate of CRTd responders (p value\u2009&lt;\u20090.05). To date, GLP-1 RA therapy may predict a reduction of AF events (HR 0.603, CI [0.411\u20130.884]), VT events (HR 0.964, CI [0.963\u20130.992]), and hospitalization for heart failure worsening (HR 0.119, CI [0.028\u20130.508]), and a higher CRT responders rate (HR 3.707, CI [1.226\u201314.570]).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>GLP-1 RA drugs in addition to conventional hypoglycemic therapy may significantly reduce systemic inflammation and circulating BNP levels in CRTd patients with diabetes, leading to a significant improvement of LVEF and of the 6\u00a0min walking test, and to a reduction of the arrhythmic burden. Consequently, GLP-1 RA drugs in addition to conventional hypoglycemic therapy may reduce hospital admissions for heart failure worsening, by increasing CRTd responders rate.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> NCT03282136. Registered 9 December 2017 \u201cretrospectively registered\u201d<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-018-0778-9","type":"journal-article","created":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T08:15:23Z","timestamp":1540196123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate"],"prefix":"10.1186","volume":"17","clinical-trial-number":[{"clinical-trial-number":"nct03282136","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5099-3790","authenticated-orcid":false,"given":"Celestino","family":"Sardu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Paolisso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosimo","family":"Sacra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Santamaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"de Lucia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ruocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Paolisso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelangela","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Marfella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,22]]},"reference":[{"issue":"1S","key":"778_CR1","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/j.amjcard.2017.05.014","volume":"120","author":"M Lehrke","year":"2017","unstructured":"Lehrke M, Marx N. Diabetes mellitus and heart failure. Am J Cardiol. 2017;120(1S):S37\u201347.","journal-title":"Am J Cardiol"},{"issue":"6","key":"778_CR2","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776\u2013803.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"778_CR3","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","volume":"29","author":"MR MacDonald","year":"2008","unstructured":"MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ, CHARM Investigators. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29(11):1377\u201385.","journal-title":"Eur Heart J"},{"issue":"1","key":"778_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12933-017-0554-2","volume":"16","author":"C Sardu","year":"2017","unstructured":"Sardu C, Barbieri M, Santamaria M, Giordano V, Sacra C, Paolisso P, Spirito A, Marfella R, Paolisso G, Rizzo MR. Multipolar pacing by cardiac resynchronization therapy with a defibrillators treatment in type 2 diabetes mellitus failing heart patients: impact on responders rate, and clinical outcomes. Cardiovasc Diabetol. 2017;16(1):75.","journal-title":"Cardiovasc Diabetol"},{"key":"778_CR5","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1056\/NEJMoa1506115","volume":"374","author":"KB Filion","year":"2016","unstructured":"Filion KB, Azoulay L, Platt RW, Dahl M, Dormuth CR, Clemens KK, Hu N, Paterson JM, Targownik L, Turin TC, Udell JA, Ernst P, for the CNODES Investigators. A multicenter observational study of GLP-1 agonist-based drugs and heart failure. N Engl J Med. 2016;374:1145\u201354.","journal-title":"N Engl J Med"},{"issue":"6","key":"778_CR6","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2337\/dc09-9029","volume":"32","author":"ES Moghissi","year":"2009","unstructured":"Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, Inzucchi SE, Ismail-Beigi F, Kirkman MS, Umpierrez GE, American Association of Clinical Endocrinologists, American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32(6):1119\u201331.","journal-title":"Diabetes Care"},{"key":"778_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13098-017-0304-3","volume":"10","author":"R Marfella","year":"2018","unstructured":"Marfella R, Sardu C, Balestrieri ML, Siniscalchi M, Minicucci F, Signoriello G, Calabr\u00f2 P, Mauro C, Pieretti G, Coppola A, Nicoletti G, Rizzo MR, Paolisso G, Barbieri M. Effects of GLP-1 agonist treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis. Diabetol Metab Syndr. 2018;10:1.","journal-title":"Diabetol Metab Syndr"},{"issue":"3","key":"778_CR8","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/dom.13122","volume":"20","author":"R Marfella","year":"2018","unstructured":"Marfella R, Sardu C, Calabr\u00f2 P, Siniscalchi M, Minicucci F, Signoriello G, Balestrieri ML, Mauro C, Rizzo MR, Paolisso G, Barbieri M. Non-ST-elevation myocardial infarction outcomes in patients with type 2 diabetes with non-obstructive coronary artery stenosis: effects of GLP-1 agonist treatment. Diabetes Obes Metab. 2018;20(3):723\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"14","key":"778_CR9","doi-asserted-by":"publisher","first-page":"e6558","DOI":"10.1097\/MD.0000000000006558","volume":"96","author":"C Sardu","year":"2017","unstructured":"Sardu C, Santamaria M, Funaro S, Sacra C, Barbieri M, Paolisso P, Marfella R, Paolisso G, Rizzo MR. Cardiac electrophysiological alterations and clinical response in cardiac resynchronization therapy with a defibrillator treated patients affected by metabolic syndrome. Medicine (Baltimore). 2017;96(14):e6558.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"778_CR10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ghir.2007.01.020","volume":"17","author":"M Petretta","year":"2007","unstructured":"Petretta M, Colao A, Sardu C, Scopacasa F, Marzullo P, Pivonello R, Fontanella L, de Caterina M, de Simone A, Bonaduce D. NT-proBNP, IGF-I and survival in patients with chronic heart failure. Growth Horm IGF Res. 2007;17(4):288\u201396.","journal-title":"Growth Horm IGF Res"},{"key":"778_CR11","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1161\/01.CIR.0000054164.99881.00","volume":"107","author":"IS Anand","year":"2003","unstructured":"Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart failure trial (Val-HeFT). Circulation. 2003;107:1278\u201383.","journal-title":"Circulation"},{"key":"778_CR12","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.jacc.2009.01.057","volume":"53","author":"D Moertl","year":"2009","unstructured":"Moertl D, Berger R, Struck J, et al. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic HF: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J Am Coll Cardiol. 2009;53:1783\u201390.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"778_CR13","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.amjcard.2008.04.008","volume":"102","author":"JM Tolosana","year":"2008","unstructured":"Tolosana JM, Madrid AH, Brugada J, Sitges M, Bolao IG, Lozano IF, Ferrer JM, Quesada A, Macias A, Marin W, Escudier JM, Gomez AA, Gimenez AM, Tamborero D, Berruezo A, Mont L. Comparison of benefits and mortality in cardiac resynchronization therapy in patients with atrial fibrillation versus patients in sinus rhythm (Results of the Spanish Atrial Fibrillation and Resynchronization [SPARE] Study). Am J Cardiol. 2008;102(4):444\u20139.","journal-title":"Am J Cardiol"},{"key":"778_CR14","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/j.1540-8167.1999.tb00263.x","volume":"10","author":"AE Tuinenburg","year":"1999","unstructured":"Tuinenburg AE, Brundel BJ, Van Gelder IC, Henning RH, Van Den Berg MP, Driessen C, Grandjean JG, Van Gilst WH, Crijns HJ. Gene expression of the natriuretic peptide system in atrial tissue of patients with paroxysmal and persistent atrial fibrillation. J Cardiovasc Electrophysiol. 1999;10:827\u201335.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"778_CR15","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1161\/CIRCULATIONAHA.109.873265","volume":"120","author":"KK Patton","year":"2009","unstructured":"Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, Kronmal RA. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation. 2009;120:1768\u201374.","journal-title":"Circulation"},{"issue":"11","key":"778_CR16","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1093\/eurjhf\/hft088","volume":"15","author":"R Marfella","year":"2013","unstructured":"Marfella R, Di Filippo C, Potenza N, Sardu C, Rizzo MR, Siniscalchi M, Musacchio E, Barbieri M, Mauro C, Mosca N, Solimene F, Mottola MT, Russo A, Rossi F, Paolisso G, D\u2019Amico M. Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders. Eur J Heart Fail. 2013;15(11):1277\u201388.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"778_CR17","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.2217\/pgs.14.76","volume":"15","author":"C Sardu","year":"2014","unstructured":"Sardu C, Marfella R, Santulli G, Paolisso G. Functional role of miRNA in cardiac resynchronization therapy. Pharmacogenomics. 2014;15(8):1159\u201368.","journal-title":"Pharmacogenomics"},{"key":"778_CR18","doi-asserted-by":"publisher","first-page":"7292564","DOI":"10.1155\/2016\/7292564","volume":"2016","author":"C Sardu","year":"2016","unstructured":"Sardu C, Barbieri M, Rizzo MR, Paolisso P, Paolisso G, Marfella R. Cardiac resynchronization therapy outcomes in type 2 diabetic patients: role of microRNA changes. J Diabetes Res. 2016;2016:7292564.","journal-title":"J Diabetes Res"},{"issue":"3","key":"778_CR19","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s12265-014-9545-9","volume":"7","author":"C Sardu","year":"2014","unstructured":"Sardu C, Marfella R, Santulli G. Impact of diabetes mellitus on the clinical response to cardiac resynchronization therapy in elderly people. J Cardiovasc Transl Res. 2014;7(3):362\u20138.","journal-title":"J Cardiovasc Transl Res"},{"issue":"21","key":"778_CR20","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1093\/eurheartj\/ehv510","volume":"37","author":"M Cikes","year":"2016","unstructured":"Cikes M, Solomon SD. Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure. Eur Heart J. 2016;37(21):1642\u201350.","journal-title":"Eur Heart J"},{"key":"778_CR21","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.hrthm.2013.02.017","volume":"10","author":"JE Schliamser","year":"2013","unstructured":"Schliamser JE, Kadish AH, Subacius H, et al. Significance of follow-up left ventricular ejection fraction measurements in the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation trial (DEFINITE). Heart Rhythm. 2013;10:838\u201346.","journal-title":"Heart Rhythm"},{"key":"778_CR22","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.jacc.2014.03.025","volume":"63","author":"V Kini","year":"2014","unstructured":"Kini V, Soufi MK, Deo R, et al. Appropriateness of primary prevention implantable cardioverter defibrillators at the time of generator replacement: are indications still met? J Am Coll Cardiol. 2014;63:2388\u201394.","journal-title":"J Am Coll Cardiol"},{"key":"778_CR23","doi-asserted-by":"publisher","first-page":"e000083","DOI":"10.1161\/JAHA.112.000083","volume":"2","author":"A Cheng","year":"2013","unstructured":"Cheng A, Dalal D, Butcher B, et al. Prospective observational study of implantable cardioverter defibrillators in primary prevention of sudden cardiac death: study design and cohort description. J Am Heart Assoc. 2013;2:e000083.","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"778_CR24","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ehj.2003.09.030","volume":"25","author":"S Ghio","year":"2004","unstructured":"Ghio S, Constantin C, Klersy C, et al. Interventricular and intraventricular dyssynchrony are common in heart failure patients, regardless of QRS duration. Eur Heart J. 2004;25(7):571\u20138.","journal-title":"Eur Heart J"},{"issue":"20","key":"778_CR25","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1001\/jama.289.20.2685","volume":"289","author":"JB Young","year":"2003","unstructured":"Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA. 2003;289(20):2685\u201394.","journal-title":"JAMA"},{"issue":"12","key":"778_CR26","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/j.jacc.2005.09.019","volume":"46","author":"JJ Bax","year":"2005","unstructured":"Bax JJ, Abraham T, Barold SS, et al. Cardiac resynchronization therapy: part 1\u2014issues before device implantation. J Am Coll Cardiol. 2005;46(12):2153\u201367.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"778_CR27","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S0735-1097(03)01042-8","volume":"42","author":"SL Higgins","year":"2003","unstructured":"Higgins SL, Hummel JD, Niazi IK, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol. 2003;42(8):1454\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"778_CR28","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1054\/jcaf.2000.9501","volume":"6","author":"MR Bristow","year":"2000","unstructured":"Bristow MR, Feldman AM, Saxon LA. Heart failure management using implantable devices for ventricular resynchronization: comparison of medical therapy, pacing, and defibrillation in chronic heart failure (COMPANION) trial. COMPANION Steering Committee and COMPANION Clinical Investigators. J Card Fail. 2000;6(3):276\u201385.","journal-title":"J Card Fail"},{"issue":"5B","key":"778_CR29","doi-asserted-by":"publisher","first-page":"130D","DOI":"10.1016\/S0002-9149(98)01014-5","volume":"83","author":"A Auricchio","year":"1999","unstructured":"Auricchio A, Stellbrink C, Sack S, et al. The pacing therapies for congestive heart failure (PATH-CHF) study: rationale, design, and endpoints of a prospective randomized multicenter study. Am J Cardiol. 1999;83(5B):130D\u20135D.","journal-title":"Am J Cardiol"},{"issue":"9A","key":"778_CR30","doi-asserted-by":"publisher","first-page":"138K","DOI":"10.1016\/S0002-9149(00)01298-4","volume":"86","author":"C Stellbrink","year":"2000","unstructured":"Stellbrink C, Auricchio A, Butter C, et al. Pacing therapies in congestive heart failure II study. Am J Cardiol. 2000;86(9A):138K\u201343K.","journal-title":"Am J Cardiol"},{"issue":"4","key":"778_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S1388-9842(01)00176-3","volume":"3","author":"JG Cleland","year":"2001","unstructured":"Cleland JG, Daubert JC, Erdmann E, et al. The CARE-HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end-points. Eur J Heart Fail. 2001;3(4):481\u20139.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"778_CR32","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1054\/jcaf.2000.20841","volume":"6","author":"WT Abraham","year":"2000","unstructured":"Abraham WT. Rationale and design of a randomized clinical trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with advanced heart failure: the Multicenter InSync Randomized Clinical Evaluation (MIRACLE). J Card Fail. 2000;6(4):369\u201380.","journal-title":"J Card Fail"},{"issue":"1","key":"778_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0735-1097(02)01932-0","volume":"40","author":"C Linde","year":"2002","unstructured":"Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol. 2002;40(1):111\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"778_CR34","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/S0002-9149(00)00716-5","volume":"85","author":"C Leclercq","year":"2000","unstructured":"Leclercq C, Victor F, Alonso C, et al. Comparative effects of permanent biventricular pacing for refractory heart failure in patients with stable sinus rhythm or chronic atrial fibrillation. Am J Cardiol. 2000;85(9):1154\u20131156, A9.","journal-title":"Am J Cardiol"},{"key":"778_CR35","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12933-016-0401-x","volume":"15","author":"B Szepietowska","year":"2016","unstructured":"Szepietowska B, Polonsky B, Sherazi S, et al. Effect of obesity on the effectiveness of cardiac resynchronization to reduce the risk of first and recurrent ventricular tachyarrhythmia events. Cardiovasc Diabetol. 2016;15:93.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"778_CR36","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jamacardio.2016.5388","volume":"2","author":"LN Marzec","year":"2017","unstructured":"Marzec LN, Peterson PN, Bao H, et al. Use of cardiac resynchronization therapy among eligible patients receiving an implantable cardioverter defibrillator insights from the National cardiovascular data registry implantable cardioverter defibrillator registry. JAMA Cardiol. 2017;2(5):561\u20135.","journal-title":"JAMA Cardiol"},{"issue":"11","key":"778_CR37","doi-asserted-by":"publisher","first-page":"4316","DOI":"10.1172\/JCI84937","volume":"125","author":"G Santulli","year":"2015","unstructured":"Santulli G, Pagano G, Sardu C, Xie W, Reiken S, D\u2019Ascia SL, Cannone M, Marziliano N, Trimarco B, Guise TA, Lacampagne A, Marks AR. Calcium release channel RyR2 regulates insulin release and glucose homeostasis. J Clin Invest. 2015;125(11):4316.","journal-title":"J Clin Invest"},{"key":"778_CR38","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/1471-2261-14-176","volume":"14","author":"C Sardu","year":"2014","unstructured":"Sardu C, Carreras G, Katsanos S, Kamperidis V, Pace MC, Passavanti MB, Fava I, Paolisso P, Pieretti G, Nicoletti GF, Santulli G, Paolisso G, Marfella R. Metabolic syndrome is associated with a poor outcome in patients affected by outflow tract premature ventricular contractions treated by catheter ablation. BMC Cardiovasc Disord. 2014;14:176.","journal-title":"BMC Cardiovasc Disord"},{"issue":"9","key":"778_CR39","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.cardfail.2006.08.211","volume":"12","author":"GG Sokos","year":"2006","unstructured":"Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12(9):694\u20139.","journal-title":"J Card Fail"},{"issue":"4","key":"778_CR40","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1007\/s00125-011-2440-x","volume":"55","author":"D Nathanson","year":"2012","unstructured":"Nathanson D, Ullman B, L\u00f6fstr\u00f6m U, Hedman A, Frick M, Sj\u00f6holm A, et al. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomized controlled clinical trial of efficacy and safety. Diabetologia. 2012;55(4):926\u201335.","journal-title":"Diabetologia"},{"issue":"7","key":"778_CR41","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/ijcp.12823","volume":"70","author":"C Sardu","year":"2016","unstructured":"Sardu C, Santamaria M, Rizzo MR, Barbieri M, di Marino M, Paolisso G, Santulli G, Marfella R. Telemonitoring in heart failure patients treated by cardiac resynchronisation therapy with defibrillator (CRT-D): the TELECART Study. Int J Clin Pract. 2016;70(7):569\u201376.","journal-title":"Int J Clin Pract"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-018-0778-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-018-0778-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-018-0778-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T16:08:23Z","timestamp":1628611703000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-018-0778-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,22]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["778"],"URL":"https:\/\/doi.org\/10.1186\/s12933-018-0778-9","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,22]]},"assertion":[{"value":"10 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"137"}}